title: Effect of LIGHT adjuvant on kinetics of T-cell responses induced by HSV-1 DNA immunization.
abstract: BACKGROUND
  Studies on efficacy of various vaccines that prevent or reduce the primary and recurrent HSV-1 infection have demonstrated the importance of cellular immunity for protection against the infection. We previously used DNA vaccination to induce cellular immunity against HSV-1 infection in mice.
  
  
  OBJECTIVE
  The aim of our study was to evaluate the effect of LIGHT; a member of TNF super family, on the kinetic of CTL response induced by HSV-1 glycoprotein B based DNA vaccine.
  
  
  METHODS
  Using a granzyme B ELISA for detection and analysis of CD8+ T cells, CTL activity was determined in the spleen of BALB/c mice at various time points after primary and booster dose of vaccination. The kinetics of CTL response to primary and secondary HSV-1 infection and DNA vaccination were compared to those induced by DNA vaccination in combination with LIGHT adjuvant in the present study.
  
  
  RESULTS
  In primary and secondary immunization, the CTL activity in the HSV injected group peaked 7 days and 12 hours post immunization, respectively. After 5 days, LIGHT could neither accelerate the CTL response compared to DNA vaccination alone nor could enhance the CTL activity in the primary and the first peak of memory response, the amount of granzyme B induced by the LIGHT containing vaccine was significantly higher than that induced by the vaccine without the adjuvant.
  
  
  CONCLUSIONS
  Although LIGHT enhances the cellular response in the booster dose of vaccination, it does not accelerate the CTL response.
authors.affiliation: Department of Virology, Tarbiat Modares University, Tehran, Iran.
authors.forename: Masumeh
authors.initials: M
authors.lastname: Gorgian Mohammady
authors.forename: Taravat
authors.initials: T
authors.lastname: Bamdad
authors.forename: Masoud
authors.initials: M
authors.lastname: Parsania
authors.forename: Hoorieh
authors.initials: H
authors.lastname: Soleimanjahi
authors.forename: Somayeh
authors.initials: S
authors.lastname: Pouyanfard
authors.forename: Hamidreza
authors.initials: H
authors.lastname: Hashemi
authors.forename: Mohammad
authors.initials: M
authors.lastname: Asghari-Jafarabadi
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D053804:Granzymes / Q000378:metabolism; D006561:Herpes Simplex / Q000276:immunology*; D018259:Herpesvirus 1, Human / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007156:Immunologic Memory; D051379:Mice; D008807:Mice, Inbred BALB C; D053326:Tumor Necrosis Factor Ligand Superfamily Member 14 / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D014765:Viral Vaccines / Q000008:administration & dosage
chemical_list: D000276:Adjuvants, Immunologic; D053326:Tumor Necrosis Factor Ligand Superfamily Member 14; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C562160:glycoprotein B, human herpesvirus 1; D053804:Granzymes